EGFR and non-small cell lung carcinoma: Osimertinib is a third-generation EGFR inhibitorapproved in 2017 for the treatment of NSCLC in patients with a specific EGFRT790M mutation that either exists de novo or is acquiredduring treatment with first-line drugs (gefitinib, erlotinib or afatinib) andis associated with resistance to these drugs.